Metabolic dysfunction-associated steatohepatitis (MASH) innovator drugs witnessed an over $2.5bn increase in the total value of partnership deals from 2020 to 2024 year-to-date (YTD), with more than $2bn forged in Q1 2024 alone, according to GlobalData’s Pharma Intelligence Center Deals Database.

MASH, previously known as nonalcoholic steatohepatitis (NASH), is a disease characterised by liver inflammation and damage caused by the accumulation of fat. Madrigal Pharmaceuticals’s Rezdiffra (resmetirom), a small molecule THRB agonist, was the first drug approved by the FDA for MASH, in March 2024. Previous interest in MASH from biopharmaceutical companies has waned due to competitive pressures and failure to demonstrate efficacy in clinical trials, causing companies to discontinue development within MASH. In June 2023, Intercept Pharmaceuticals discontinued development of its Ocaliva (obeticholic acid) in MASH and all MASH-related investment following the FDA’s rejection of Ocaliva’s submission for regulatory approval. Other examples of discontinued development in MASH include Genfit’s oral NR1C1/NR1C2 dual agonist elafibranor in July 2020 and Bristol Myers Squibb’s pegbelfermin in November 2021, both due to failure to demonstrate clinical efficacy in their Phase III trial readouts. However, interest in MASH drug development has returned in light of the success of GLP-1 obesity drugs and their potential efficacy in MASH, as demonstrated by Eli Lilly’s Zepbound (tirzepatide; also known as Mounjaro for type 2 diabetes) in its Phase II SYNERGY-NASH trial readout.

Partnership deals for innovator drugs involved in MASH saw a resurgence in activity of over $2.5bn in deal value from 2023 to 2024YTD. Figure 1 (above) shows a cumulative deal value total of over $5.7bn from 2018 to 2024YTD, according to GlobalData’s Pharma Intelligence Center Deals Database, where 2024YTD already surpassed the total deal value reported for 2018, marking the highest total deal value in a year.

In January 2024, Boehringer Ingelheim signed a partnership deal with China-based biotech Suzhou Ruibo Biotechnology and its Sweden-based subsidiary Ribocure Pharmaceuticals to discover and develop siRNA therapeutics for MASH using Ribocure’s RIBO-GalSTAR platform. The “multi-target collaboration” is valued at over $2bn, representing the largest partnership deal for MASH drugs of all time. This reinforces Boehringer’s interest in MASH, with Boehringer’s GLP-1/GLU dual agonist survodutide—co-developed with Zealand Pharma—currently in Phase II trials for MASH.

Meanwhile, Novo Nordisk entered a co-development partnership deal with US-based Cellarity valued at over $500m, aimed at using Cellarity’s artificial intelligence (AI) platform to discover and develop a small molecule drug for MASH. This follows Novo Nordisk’s co-development deal with Gilead Sciences, forged in March 2021, to conduct a Phase II trial of its GLP1R agonist Ozempic (semaglutide) with Gilead’s fixed-dose combination of FXR agonist cilofexor and ACC inhibitor firsocostat for the treatment of patients with compensated cirrhosis due to MASH.

The recent increase in partnership deals involving innovative MASH drugs in 2024YTD involved large biopharmaceutical companies with a history of having previously engaged in MASH drug development, such as Boehringer and Novo Nordisk. Given the large number of MASH drugs in clinical development, including GLP-1 agonists, there may be an increase in partnership deals and mergers and acquisitions involving late-stage clinical MASH drugs over this year. Nonetheless, biopharmaceutical companies developing innovator MASH drugs will have to match the safety and efficacy benchmark established by Madrigal’s Rezdiffra or possess a differentiated value proposition to succeed in capturing market share from Madrigal.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

View profiles in store

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Submit

UK USA Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Côte d"Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Réunion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo

Industry * Academia & Education Aerospace, Defense & Security Agriculture Asset Management Automotive Banking & Payments Chemicals Construction Consumer Foodservice Government, trade bodies and NGOs Health & Fitness Hospitals & Healthcare HR, Staffing & Recruitment Insurance Investment Banking Legal Services Management Consulting Marketing & Advertising Media & Publishing Medical Devices Mining Oil & Gas Packaging Pharmaceuticals Power & Utilities Private Equity Real Estate Retail Sport Technology Telecom Transportation & Logistics Travel, Tourism & Hospitality Venture Capital

Tick here to opt out of curated industry news, reports, and event updates from Pharmaceutical Technology.

Submit and download

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

*Note: Includes all announced and completed partnership deals globally from 2018 to 2024YTD. Includes deals where at least one drug involved is developed for metabolic dysfunction-associated steatohepatitis (MASH) with innovator drug type, where stages of development discovery, preclinical, Phase I, Phase II, Phase III, pre-registration, and marketed are considered.